Show simple item record

dc.contributor.authorOzmen, Vahit
dc.contributor.authorTukenmez, Mustafa
dc.contributor.authorCabıoglu, Neslihan
dc.contributor.authorIgci, Abdullah
dc.contributor.authorSaip, Pinar
dc.contributor.authorYAZICI, Hülya
dc.contributor.authorOzmen, Tolga
dc.contributor.authorEmiroglu, Selman
dc.contributor.authorMuslumanoglu, Mahmut
dc.contributor.authorÖzkurt, Enver
dc.date.accessioned2023-05-29T12:47:59Z
dc.date.available2023-05-29T12:47:59Z
dc.identifier.citationEmiroglu S., Özkurt E., Cabıoglu N., Igci A., Saip P., YAZICI H., Ozmen T., Ozmen V., Muslumanoglu M., Tukenmez M., "Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with BRCA1 or BRCA2 Germline Mutation?", Breast Cancer: Targets and Therapy, cilt.15, ss.163-173, 2023
dc.identifier.issn1179-1314
dc.identifier.otherav_22771c10-7f88-4649-b756-36d8bceb5381
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/188890
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/22771c10-7f88-4649-b756-36d8bceb5381/file
dc.identifier.urihttps://doi.org/10.2147/bctt.s395054
dc.description.abstractBackground: The optimal surgical therapy for newly diagnosed breast cancer with germline mutations in susceptibility genes is still uncertain for many physicians. In this study, we aimed to determine the efficacy of breast conserving surgery (BCS) in breast cancer patients with BRCA1 or BRCA2 mutation by assessing its outcomes and locoregional recurrence (LR) rates. Materials and Methods: Seventy-five patients operated with BCS or mastectomy for breast cancer between 2006 and 2017 and had BRCA1 or BRCA2 mutation were included in the study. Effects of the performed breast surgery and clinicopathological characteristics on surgical outcomes, LR rates and survival were analyzed with showing the distribution of BRCA1 and BRCA2 germline mutations. Results: The median age of the patients was 42 years (20–77). BRCA1 mutations were found in 46 (61.3%) patients and BRCA2 mutations in 29 (38.7%) patients. Compared to BRCA2 carriers, BRCA1 carriers were more likely to have higher tumor grade (84.8% vs 44.8%; p = 0.001) and non-luminal subtype tumors (67.4% vs 13.8%; p = 0.001). A total of 44 (58.7%) patients underwent unilateral mastectomy and 31 (41.3%) patients underwent BCS. At a median follow-up time of 60 (12–240) months, LR was observed in 6 patients equally divided in both BCS and mastectomy groups. LR rates were slightly higher after BCS versus mastectomy (9.7% and 6.8%, respectively). Additionally, there were no statistically significant differences in disease-free survival (DFS) and disease-specific survival (DSS) rates after 10 years in the BCS group versus the mastectomy group (p = 0.117 and 0.109, respectively), but in fact, the rates were better in the BCS group. Conclusion: Our findings indicate that BCS may serve as an efficacious alternative to mastectomy for breast cancer patients with BRCA1 or BRCA2 mutation. Additionally, tumor size, lymph node positivity, and TNM stage should be taken into consideration for a better surgical decision-making.
dc.language.isoeng
dc.subjectONKOLOJİ
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.titleIs Breast Conserving Surgery Efficacious in Breast Cancer Patients with BRCA1 or BRCA2 Germline Mutation?
dc.typeMakale
dc.relation.journalBreast Cancer: Targets and Therapy
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Cerrahi Tıp Bilimleri Bölümü
dc.identifier.volume15
dc.identifier.startpage163
dc.identifier.endpage173
dc.contributor.firstauthorID4257410


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record